Illumina Q3 Revenues Down 12 Percent

Oct 29, 2020

|

NEW YORK – Illumina reported after the close of the market on Thursday that its third quarter 2020 revenues fell 12 percent year over year.

For the three months ended Sept. 27, 2020, Illumina recorded total revenues of $794 million compared to $907 million a year ago, beating the consensus Wall Street estimate of $715.9 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Letter Urges New Inquiry

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

Great Apes Get Shots, Too

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Woodcock on Vaccines, More

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

Science Paper Examines Molecular Contributors to Kidney Fibrosis

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.

Featured White Papers

Single-cell DNA Analysis of a Novel Acute Erythroid Leukemia (AEL) CRISPR Induced Mouse Model

Analyze, Interpret and Report NGS Data Faster than Ever Before

Single-cell Sequencing 101: DNA & Multiomics for Precision Medicine

B Cell Isolation for Single Cell Genomics

Mar

09

Featured Webinar

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

The growth of next-generation sequencing (NGS) testing presents both opportunities and challenges for clinical, informatics, and laboratory teams.

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

16

Featured Webinar

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Wastewater based epidemiology (WBE) has been established as a viable, valuable, and cost-effective means to monitor infectious disease within a community.

Mar

18

Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Viruses mutate as they strive to thrive in response to selective pressures.

Menu

Illumina Q3 Revenues Down 12 Percent

To read the full story....

Breaking News

Cue Health Over-the-Counter COVID-19 Test Gets FDA Emergency Use Authorization

Fauna Bio Gets $373K NIH Grant to Study Animal Genomes for Potential Drug Targets

New Products Posted to GenomeWeb: Purigen Biosystems, Zymo Research, Qiagen, More

People in the News: New Appointments at Precipio, ERS Genomics, Omniome, PierianDx, More

In Brief This Week: Invenio Genetics, Swift Biosciences, Caris Life Sciences, and More

Abbott Gets FDA EUA for Test That Detects Coronavirus, Three Other Respiratory Infections

The Scan

Letter Urges New Inquiry

Great Apes Get Shots, Too

Woodcock on Vaccines, More

Science Paper Examines Molecular Contributors to Kidney Fibrosis

Featured White Papers

Implementation of Whole-Exome and Virtual Panel Testing for Rare Disease at a Children’s Hospital

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

The Predictive Power of Poop: COVID-19 Wastewater Surveillance to Inform Public Health Decisions in Colorado

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

What's Popular?

At AGBT, Two Labs Share SARS-CoV-2 Genomic Surveillance Experience

Illumina Receives Medical Device Registration in Russia for NextSeq 550 Dx Sequencer, Reagents

Fulgent Genetics Q4 Revenues Skyrocket

Agilent Charges Into Liquid Biopsy Space with Resolution Biosciences Acquisition

Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M

Sponsorships